Literature DB >> 25592633

Sunitinib in thymic carcinoma: enigmas still unresolved.

Alexander Marx1, Cleo-Aron Weis2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25592633     DOI： 10.1016/S1470-2045(15)70010-0

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  4 in total

Review 1.  The 2015 World Health Organization Classification of Tumors of the Thymus: Continuity and Changes.

Authors:  Alexander Marx; John K C Chan; Jean-Michel Coindre; Frank Detterbeck; Nicolas Girard; Nancy L Harris; Elaine S Jaffe; Michael O Kurrer; Edith M Marom; Andre L Moreira; Kiyoshi Mukai; Attilio Orazi; Philipp Ströbel
Journal:  J Thorac Oncol       Date:  2015-10       Impact factor: 15.609

Review 2.  [Thymic carcinomas].

Authors:  P Ströbel; C-A Weis; A Marx
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

Review 3.  [Thymomas].

Authors:  A Marx; C-A Weis; P Ströbel
Journal:  Pathologe       Date:  2016-09       Impact factor: 1.011

4.  TFE3-PD-L1 axis is pivotal for sunitinib resistance in clear cell renal cell carcinoma.

Authors:  Xudong Guo; Ruxia Li; Qiulei Bai; Shaobo Jiang; Hanbo Wang
Journal:  J Cell Mol Med       Date:  2020-11-03       Impact factor: 5.295
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.